The National Wilms Tumor Study Group (NWTS) is a cancer research cooperative group in the United States formed to study a type of kidneytumor that affects children called Wilms' tumor. In 2001, NWTS merged with several other pediatric oncology cooperative groups to create the Children's Oncology Group (COG). However, the NWTS is still active in name today completing follow-up of the late effects of treatment for patients previously enrolled in its trials. The acronym NWTS is pronounced like the word "nitwits".
The NWTS was formed in 1969 by member institutions from Children's Cancer Study Group (CCG), Southwest Oncology Group (SWOG), and CALGB, the latter two which later merged to form the Pediatric Oncology Group (POG). The NWTS was created with the purpose of improving survival of children with Wilms' tumor. NWTS studies were conducted at over 250 pediatric oncology treatment centers in the United States, Canada, and other countries. Approximately 70-80% of patients with Wilms' tumor were enrolled on NWTS treatment protocols, totalling 440 patients per year.
NWTS ran five clinical trials, designated NWTS-1 to NWTS-5. The first four were randomized trials, whereas NWTS-5 was a clinical trial designed to look primarily at biologic prognostic factors and was not randomized. NWTS-5 was completed in 2003.
Wilms' tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in children, rarely in adults. It is named after Max Wilms, the German surgeon (1867–1918) who first described it.
Rhabdomyosarcoma (RMS), is a highly aggressive form of cancer that develops from mesenchymal cells that have failed to fully differentiate into myocytes of skeletal muscle. Cells of the tumor are identified as rhabdomyoblasts.
In the field of medical treatment, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth, which results in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.
A blastoma is a type of cancer, more common in children, that is caused by malignancies in precursor cells, often called blasts. Examples are nephroblastoma, medulloblastoma, and retinoblastoma. The suffix -blastoma is used to imply a tumor of primitive, incompletely differentiated cells, e.g., chondroblastoma is composed of cells resembling the precursor of chondrocytes.
The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.
The Pediatric Oncology Group (POG) was a U.S. and Canadian clinical trial cooperative group created with the mission of studying childhood cancers. It was formed by the merger of the pediatric divisions of two other cooperative groups, the Southwest Oncology Group (SWOG) and the CALGB. In 2000, POG merged with several other pediatric cooperative groups to form the Children's Oncology Group (COG). This merger has seen its fair share of problems, especially with regard to integrating the various databases associated with each individual cooperative group. One such initiative to consolidate these databases involves caBIG or the cancer Biomedical Informatics Grid, which is guided and supported by the National Cancer Institute (NCI) in Bethesda, Maryland.
The Intergroup Rhabdomyosarcoma Study Group (IRS) was a U.S. and Canadian clinical trial cooperative group created with the mission of studying childhood cancers. In 2000, IRS merged with several other pediatric cooperative groups to form the Children's Oncology Group (COG). This merger has seen its fair share of problems, especially with regard to integrating the various databases associated with each individual cooperative group. One such initiative to consolidate these databases involves caBIG, or cancer BIG, which is guided and supported by the National Cancer Institute (NCI) in Bethesda, Maryland. They published a report on cancer treatment protocols published by the National Institute of Health in 2001, and a separate report in 2011 on improving outcomes for patients with low-risk embryonal rhabdomyosarcoma.
Medulloblastoma is a common type of primary brain cancer in children. It originates in the part of the brain that is towards the back and the bottom, on the floor of the skull, in the cerebellum, or posterior fossa.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
An atypical teratoid rhabdoid tumor (AT/RT) is a rare tumor usually diagnosed in childhood. Although usually a brain tumor, AT/RT can occur anywhere in the central nervous system (CNS), including the spinal cord. About 60% will be in the posterior cranial fossa. One review estimated 52% in the posterior fossa, 39% are supratentorial primitive neuroectodermal tumors (sPNET), 5% are in the pineal, 2% are spinal, and 2% are multifocal.
Jessica Kandel is the Surgeon-in-Chief, University of Chicago Medical Center Comer Children's Hospital, Mary Campau Ryerson Professor of Surgery and Chief, Section of Pediatric Surgery, and the Vice-Chair for Pediatric Surgical Services, appointed August 1, 2013.
Hope & Heroes is a 501(c)(3) non-profit organization based at Columbia University Medical Center (CUMC) in New York City. Hope & Heroes supports the Division of Pediatric Hematology, Oncology & Stem Cell Transplantation at Columbia University Medical Center. Hope & Heroes funds the life-saving work on childhood cancer and blood disorders at Columbia University Medical Center—including cutting-edge research, support for families, and care that always puts children first.
Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
Racotumomab is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
Professor Minesh P Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
The Collaborative Ependymoma Research Network (CERN) Foundation is a nonprofit organization composed of scientists and adult and pediatric cancer researchers who work together to develop new treatments for Ependymoma, a type of primary brain or spinal cord tumor that occurs in both children and adults, and improve the outcomes and care of patients. The organization is headquartered in Dayton, Ohio, USA.
Childhood cancer is cancer in a child. In the United States, an arbitrarily adopted standard of the ages used are 0–14 years inclusive, that is, up to 14 years 11.9 months of age. However, the definition of childhood cancer sometimes includes adolescents between 15–19 years old. Pediatric oncology is the branch of medicine concerned with the diagnosis and treatment of cancer in children.
Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer. Radiation therapy is commonly used to treat known tumor occurrence in the brain, either with highly precise stereotactic radiation or therapeutic cranial irradiation. By contrast, PCI is intended as preemptive treatment in patients with no known current intracranial tumor, but with high likelihood for harboring occult microscopic disease and eventual occurrence. For small-cell lung cancer with limited and select cases of extensive disease, PCI has shown to reduce recurrence of brain metastases and improve overall survival in complete remission.
PROSTVAC is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are focusing on more advanced cases of metastatic castration-resistant prostate cancer (mCRPC). PROSTVAC is a vaccine designed to enable the immune system to recognize and attack prostate cancer cells by triggering a specific and targeted T cell immune response to cancer cells that express the tumor-associated antigen prostate-specific antigen (PSA).
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
